Novo Nordisk sues Hims & Hers over ‘knock-off Wegovy’

Novo Nordisk has filed suit against telemedicine provider Hims & Hers, alleging patent infringement by marketing and selling compounded semaglutide products marketed as copies of Ozempic and Wegovy and asking a federal court to declare infringement, permanently enjoin sales and award damages. The complaint stresses patient-safety and regulatory concerns after a multiyear semaglutide shortage ended in October 2024, notes Novo’s prior commercial partnerships with telemedicine providers that dissolved when compounded sales continued, and highlights potential revenue and market-share implications for Hims & Hers if sales are blocked while reinforcing Novo’s IP protections.

Analysis

Market structure: Novo Nordisk (NVO) is the clear near-term beneficiary as a successful suit would blunt competing compounded semaglutide supply and defend branded pricing/margin power; Eli Lilly (LLY) and other GLP‑1 innovators also benefit from reduced downward pricing pressure. Direct losers are Hims & Hers (HIMS) and compounding-focused players whose revenue/GM exposure to GLP‑1s could face an immediate legal shutdown; expect elevated implied volatility and potential equity drawdowns of 20–50% for exposed telemedicine/compounders if injunctions follow. Cross-asset: HIMS credit spreads and equity vols should widen; NVO credit impact immaterial but modest positive for Danish krona (DKK) sentiment and for large-cap pharma equities.

Risk assessment: Tail risks include a plaintiff loss or regulatory guidance favoring compounding that permanently commoditizes semaglutide, which could erode NVO pricing by an outsized 10–30% over years. Timing: expect headline volatility in days, court motions/preliminary injunction news within 30–90 days, and definitive rulings in 6–18 months; long-term patent and biosimilar pressure plays out over multiple years. Hidden dependencies include API sourcing and pharmacy litigation spillovers; catalysts are preliminary injunction rulings, FDA statements, and settlement/royalty deals.

Trade implications: Direct actionable plays are long NVO (6–12 month horizon) and short HIMS (3–6 month horizon); prefer defined‑risk option structures — buy HIMS 3‑month puts (30–45 delta) or 3‑month put spreads, and NVO 9–12 month call spreads 5–10% OTM to limit capital. Relative value: pair trade long NVO / short HIMS equal dollar exposure; rotate into large-cap biotech (NVO, LLY) and trim telemedicine/compounding small caps by 30–50% of benchmark weight. Entry/exit: initiate within next 2–10 trading days on sustained headlines; set stop-losses at 15–20% adverse move and trim 50% on 30% realized move.

Key Decisions for Investors

• Establish a 2–3% long position in NVO (Novo Nordisk) with a 6–12 month horizon; hedge with a 9–12 month 5–10% OTM call spread to size upside while limiting capital risk.
• Initiate a 2% short exposure to HIMS (Hims & Hers) via 3‑month put spreads (30–45 delta buys, 10–15% OTM) targeting 30–50% downside within 3–6 months; set stop-loss at a 20% adverse move.
• Implement a pair trade: long NVO (equal dollar) / short HIMS (equal dollar) sized to 3–4% net portfolio exposure to capture relative enforcement outcomes; close or rebalance on a 25–30% move in either leg.
• Reduce benchmark weight in telemedicine/compounding-exposed small caps by 30–50% and rotate into large-cap GLP‑1 beneficiaries (NVO, LLY) over next 30 days as litigation risk clears.
• Monitor three triggers for position adjustments: (1) preliminary injunction decision within 30–90 days, (2) FDA enforcement or guidance within 60 days, (3) any announced settlement/licensing — act to close HIMS shorts and materially trim NVO longs if a broad licensing deal is confirmed.